Up next

Autoplay

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

0 Views • 07/16/23
Share
Embed
administrator
administrator
Subscribers
0

Visit http://www.ecancer.org for more

Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay